New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
07:09 EDTNNVCNanoViricides says drug candidates for MERS ready for animal testing
NanoViricides reported that it has designed and synthesized novel nanoviricides drug candidates in quantities sufficient for testing in animals infected with the MERS Corona Virus. The company said, "Using our platform technology, NanoViricides has already developed novel drug candidates against the MERS virus that mimic the MERS virus binding to the host cell. The company developed ligands that are designed to bind to the MERS coronavirus spike protein, in the same fashion that the cognate receptor of the virus, DPP-IV, binds to the virus. We performed the ligand design using well established molecular modeling techniques, based on published data regarding the MERS coronavirus spike protein and DPP-IV binding. The ligands were then chemically attached to the nanomicelle base polymer, thus making the nanoviricides drug candidates against the MERS virus. The company has already successfully scaled up the synthesis to multi-gram scale, sufficient for animal testing, and can easily scale the processes to make kilogram quantities for widespread application in human patients if they are found to be effective and safe."
News For NNVC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
09:14 EDTNNVCNanoViricides provides quarterly report
NanoViricides filed its quarterly report with the SEC estimating that it now has approximately $36.4M of current assets plus restricted cash as of December 31, 2014. The company's operating expenditure during this quarter was approximately $1.9M. Shareholder equity stood at approximately $30.5M for the quarter. The company reported that all of its drug development programs are progressing satisfactorily and that it will continue to provide updates as appropriate. The company's anti-Ebola nanoviricide drug candidates have been sent for testing at a prestigious BSL4 facility in the .S. The company has the ability to produce sufficient quantities of a successful drug candidate for potential field use. The company estimates that the cash in hand is sufficient to enable initial human clinical trials of injectable FluCide drug candidate, as well as possibly to advance another drug candidate towards initial human clinical trials.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use